GRFS (Grifols SA) רווחיות מכירות לפי רווח גולמי

Grifols, S.A. (GRFS) dependence on government procurement for the treatment of severe immune pathologies is evident in the gross margin, where the indicator stands at 37.10. Business stability is based on the sale of albumin and immunoglobulins. The risks of narrow specialization in plasma are offset by the company's global dominance and its ownership of an extensive network of proprietary raw material collection centers.
פילוחים אנליטיים ודוחות נתונים של חברת grifols.com (GRFS)

Gross margin measures the portion of revenue remaining after deducting direct production costs, allowing for an assessment of operational efficiency and the business's pricing power. For Grifols, S.A., the current value of 37.10 reflects the profitability of the closed-loop plasma processing cycle; analyzing the target gross margin helps investors understand how successfully the company monetizes its proprietary fractionation technologies.